VolitionRX (NYSEAMERICAN:VNRX) Releases Quarterly Earnings Results, Hits Expectations

VolitionRX (NYSEAMERICAN:VNRX) announced its quarterly earnings results on Tuesday. The medical research company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05), FiscalAI reports. The company had revenue of $0.45 million during the quarter, compared to analyst estimates of $0.71 million.

VolitionRX Price Performance

NYSEAMERICAN VNRX traded up $0.01 on Tuesday, reaching $0.20. The company had a trading volume of 6,929,788 shares, compared to its average volume of 28,654,266. VolitionRX has a 1 year low of $0.17 and a 1 year high of $0.94. The firm has a 50-day moving average of $0.22 and a 200-day moving average of $0.34. The firm has a market capitalization of $27.39 million, a PE ratio of -0.88 and a beta of 1.33.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VNRX. Virtu Financial LLC purchased a new position in shares of VolitionRX in the third quarter valued at $28,000. Northwestern Mutual Wealth Management Co. purchased a new stake in VolitionRX during the 2nd quarter worth $52,000. Geode Capital Management LLC lifted its holdings in VolitionRX by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after buying an additional 85,816 shares in the last quarter. Jane Street Group LLC acquired a new position in VolitionRX in the 4th quarter worth $28,000. Finally, Squarepoint Ops LLC purchased a new position in VolitionRX in the 4th quarter valued at about $34,000. 8.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

VNRX has been the topic of several research analyst reports. Maxim Group lowered VolitionRX from a “buy” rating to a “hold” rating in a research note on Wednesday, December 3rd. D. Boral Capital reiterated a “buy” rating and set a $3.00 price objective on shares of VolitionRX in a research note on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, VolitionRX presently has an average rating of “Buy” and an average target price of $2.50.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.